4 research outputs found
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors
The increasing resistance to antibacterials commonly employed in the clinic and the growth of multidrug resistant strains suggest that the development of new therapeutic approaches should be of primary concern. In this context, EPIs may restore life to old drugs. In the present work, the EPI activity of the COX-2 inhibitor celecoxib was confirmed and a new class of pyrazolo[4,3-c][1,2]benzothiazine 5,5-dioxide analogues acting as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump was identified
Pyrazolo[4,3-<i>c</i>][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors
The increasing resistance to antibacterials commonly
employed in the clinic and the growth of multidrug resistant strains
suggest that the development of new therapeutic approaches should
be of primary concern. In this context, EPIs may restore life to old
drugs. In the present work, the EPI activity of the COX-2 inhibitor
celecoxib was confirmed and a new class of pyrazolo[4,3-<i>c</i>][1,2]benzothiazine 5,5-dioxide analogues acting as inhibitors of
the Staphylococcus aureus NorA multidrug
efflux pump was identified
Re-evolution of the 2‑Phenylquinolines: Ligand-Based Design, Synthesis, and Biological Evaluation of a Potent New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors to Combat Antimicrobial Resistance
Overexpression of efflux pumps is
an important mechanism by which
bacteria evade the effects of antimicrobial agents that are substrates.
NorA is a Staphylococcus aureus efflux
pump that confers reduced susceptibility to many structurally unrelated
agents, including fluoroquinolones, biocides, and dyes, resulting
in a multidrug resistant (MDR) phenotype. In this work, a series of
2-phenylquinoline derivatives was designed by means of ligand-based
pharmacophore modeling in an attempt to identify improved S. aureus NorA efflux pump inhibitors (EPIs). Most
of the 2-phenylquinoline derivatives displayed potent EPI activity
against the <i>norA</i> overexpressing strain SA-1199B.
The antibacterial activity of ciprofloxacin, when used in combination
with some of the synthesized compounds, was completely restored in
SA-1199B and SA-K2378, a strain overexpressing <i>norA</i> from a multicopy plasmid. Compounds <b>3m</b> and <b>3q</b> also showed potent synergistic activity with the ethidium bromide
dye in a strain overexpressing the MepA MDR efflux pump